Table 1 Baseline demographic and clinical characteristics of patients undergoing NSM or SSM.
Total (N = 87) | NSM (n = 58) | SSM (n = 29) | P value* | |
|---|---|---|---|---|
Age, years | 0.701 | |||
Mean (SD) | 41.6 (8.4) | 41.4 (8.2) | 42.1 (8.9) | |
Median (Q1, Q3) | 41 (35, 48) | 41 (35.75, 48) | 42 (34.5, 49.5) | |
Range | 24–64 | 24–64 | 28–59 | |
BMI, kg/m2 | 0.561 | |||
Mean (SD) | 21.3 (2.6) | 21.4 (2.5) | 21.0 (2.8) | |
Median (Q1, Q3) | 21.1 (19.8, 23.0) | 21.1 (19.6, 23.2) | 21.1 (20.1, 22.5) | |
Range | 17.1–30.5 | 17.1–30.5 | 17.1–26.2 | |
Preoperative breast size, n (%) | 0.921 | |||
A | 17 (19.5) | 11 (19.0) | 6 (20.7) | |
B | 57 (65.5) | 39 (67.2) | 18 (62.1) | |
C | 10 (11.5) | 6 (10.3) | 4 (13.8) | |
D | 3 (3.4) | 2 (3.4) | 1 (3.4) | |
Marital status, n (%) | 1.000 | |||
Married | 82 (94.3) | 54 (93.1) | 28 (96.6) | |
Single | 4 (4.6) | 3 (5.2) | 1 (3.4) | |
Divorced | 1 (1.1) | 1 (1.7) | 0 (0.0) | |
Hypertension, n (%) | 0.106 | |||
No | 83 (95.4) | 57 (98.3) | 26 (89.7) | |
Yes | 4 (4.6) | 1 (1.7) | 3 (10.3) | |
Diabetes, n (%) | 0.550 | |||
No | 85 (97.7) | 56 (96.6) | 29 (100.0) | |
Yes | 2 (2.3) | 2 (3.4) | 0 (0.0) | |
Offspring, n (%) | 0.464 | |||
No | 9 (10.3) | 7 (12.1) | 2 (6.9) | |
Yes | 71 (81.6) | 45 (77.6) | 26 (89.7) | |
Unknown | 7 (8.0) | 6 (10.3) | 1 (3.4) | |
Previous history of breast surgery, n (%) | 0.219 | |||
No | 60 (69.0) | 37 (63.8) | 23 (79.3) | |
Yes | 27 (31.0) | 21 (36.2) | 6 (20.7) | |
Menopausal status, n (%) | 0.261 | |||
No | 78 (89.7) | 50 (86.2) | 28 (96.6) | |
Yes | 9 (10.3) | 8 (13.8) | 1 (3.4) | |
Family history of breast cancer, n (%) | 1.000 | |||
No | 81 (93.1) | 54 (93.1) | 27 (93.1) | |
Yes | 6 (6.9) | 4 (6.9) | 2 (6.9) | |
Education level, n (%) | 0.629 | |||
High school and below | 36 (41.4) | 26 (44.8) | 10 (34.5) | |
Associate degree | 9 (10.3) | 6 (10.3) | 3 (10.3) | |
Bachelor’s degree or above | 42 (48.3) | 26 (44.8) | 16 (55.2) | |
Annual household income, n (%) | 0.120 | |||
Less than ¥100,000 | 34 (39.1) | 26 (44.8) | 8 (27.6) | |
¥100,000–¥200,000 | 31 (35.6) | 21 (36.2) | 10 (34.5) | |
¥200,000–¥300,000 | 22 (25.3) | 11 (19.0) | 11 (37.9) | |
Breast cancer stage, n (%) | 0.014 | |||
0 | 23 (26.4) | 20 (34.5) | 3 (10.3) | |
I–II | 60 (69.0) | 37 (63.8) | 23 (79.3) | |
III | 4 (4.6) | 1 (1.7) | 3 (10.3) | |
Molecular subtypes, n (%) | 0.035 | |||
Luminal A | 28 (32.2) | 23 (39.7) | 5 (17.2) | |
Luminal B | 27 (31.0) | 12 (20.7) | 15 (51.7) | |
Triple-negative | 7 (8.0) | 6 (10.3) | 1 (3.4) | |
HER2-positive | 21 (24.1) | 14 (24.1) | 7 (24.1) | |
Unknown | 4 (4.6) | 3 (5.2) | 1 (3.4) |
